Aktienanalyse zu Allarity Therapeutics Inc (ALLR)ALLRAllarity Therapeutics Inc

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Allarity Therapeutics is currently a hold. The stock is trading at $0.96, which is 18.1% above its 52-week low of $0.77 but significantly below its 52-week high of $1.84. The recent 5-day change of +10.58% shows some positive momentum, but the year-to-date change of -15.57% indicates longer-term struggles. Additionally, the RSI of 49.058 suggests the stock is neither overbought nor oversold, indicating a neutral position. The main risk is the projected negative earnings per share of -$0.21 for the next earnings report on November 13, 2026, which could impact investor sentiment negatively.